Nationwide Study Shows Resveratrol Impacts Alzheimer’s Biomarker

Nationwide Study Shows Resveratrol Impacts Alzheimer’s Biomarker
Results from the largest nationwide study investigating long-term high-dose resveratrol in patients with mild to moderate Alzheimer’s disease (AD) showed that a specific a biomarker that declines with disease progression was stabilized in patients who received resveratrol in its purified form. The results, published online in Neurology, “are very interesting,” according to the study’s principal investigator, R. Scott Turner, MD, PhD, director of the Memory Disorders Program at Georgetown University Medical Center (pictured).  Turner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol. “This is a single, small study with findings that call for further research to interpret properly.” Resveratrol is found in dark chocolate, raspberries, red grapes, as well as in some red wines. Since pure synthetic (pharmaceutical-grade) resveratrol is not available commercially, the team of researchers required an “investigational new drug” application by the U.S. Food and Drug Administration. The study was a Phase II, randomized, double-blind, placebo-controlled, clinical trial in patients with mild to moderate dementia due to AD. A total of 119 patients were enrolled in the 12 months trial and the highest dose of resveratrol evaluated was one gram given orally twice per day. Results showed that those patients who received increasing doses of resvera
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *